A fifty-year-old patient was tested positive at the beginning of July with mild symptoms of cough and sore throat. Three months after the previous infection he experienced many harsh symptoms including high fever, shortness of breath, and hypoxia. Two patients in New Jersey, for instance, appear to have contracted Covid-19 a second time almost two months after fully recovering from their first infection. Daniel Griffin, a physician and researcher at Columbia University in New York, recently described a case of presumed reinfection on the This Week in Virology podcast. It’s possible to get reinfected by the virus, the period of lasting may differ. An estimated 40 to 45 percent of people with Covid-19 may be asymptomatic, and others will have a mild illness with no lasting symptoms. But Nichols is one of many Covid-19 patients who are finding their recovery takes far longer than the two weeks the World Health Organization says people with mild cases can expect.
(The WHO says those with severe or critical cases can expect three to six weeks of recovery.)
A vaccine may not be enough to end the
pandemic?
“This is an extraordinary time we’re living in right now,” said Anna Durbin, a vaccine researcher and a professor of international health at the Johns Hopkins School of Public Health. “The pandemic is motivating a lot of [vaccine] efforts around the world.”One variable shaping effectiveness is how quickly the virus mutates. A faster rate of mutation would increase the chance that the vaccine would not generate a helpful immune response to the virus.
SARS-CoV-2, the virus behind Covid-19, is a single-stranded RNA virus. Such viruses are notorious for high mutation rates, but those mutations don’t necessarily occur in a way that would weaken protections from a vaccine. In fact, evidence seems to show that SARS-CoV-2 may have a relatively slow mutation rate for an RNA virus, increasing the chances that a vaccine would offer long-term protection. “On the other hand, the vaccines will likely induce immunity that is short-lived and incomplete, ” said Paul Offit, director of the Vaccine Education Center at the Children’s Hospital of Philadelphia.
People’s Vaccine.
A pandemic needs international coordination. While researchers are sharing data about Covid-19 across boundaries, it’s not clear that nations agree on how to collaborate on making and distributing the vaccine. The US, for instance, has tried to lure vaccine developers to the country to make vaccines for limited US use. But the World Health Organization has called for sharing vaccine intellectual property free among companies and countries. Otherworld leaders have called for a people’s vaccine to Covid-19 to be made available to all countries free of charge.
Eduindex News 